Cargando…

Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data

INTRODUCTION: We aimed to clarify medical expenses in Japanese individuals before and after major depressive disorder (MDD) diagnosis, and to determine whether MDD treatment also reduces medical costs for comorbid physical conditions. METHODS: This was an exploratory, descriptive, retrospective anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Yoshinori, Mishiro, Izumi, Fujimoto, Shinji, Nakajima, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989836/
https://www.ncbi.nlm.nih.gov/pubmed/34729704
http://dx.doi.org/10.1007/s12325-021-01963-9
_version_ 1784683257946701824
author Cho, Yoshinori
Mishiro, Izumi
Fujimoto, Shinji
Nakajima, Tadashi
author_facet Cho, Yoshinori
Mishiro, Izumi
Fujimoto, Shinji
Nakajima, Tadashi
author_sort Cho, Yoshinori
collection PubMed
description INTRODUCTION: We aimed to clarify medical expenses in Japanese individuals before and after major depressive disorder (MDD) diagnosis, and to determine whether MDD treatment also reduces medical costs for comorbid physical conditions. METHODS: This was an exploratory, descriptive, retrospective analysis of insurance claims data from JMDC Inc. Cohort A included individuals aged 18–64 years between January 2015 and December 2019. Cohorts B and C included Cohort A individuals with diabetes/hypertension (‘chronic disease’), and sleep/anxiety disorders (‘high depression risk’), respectively. Individuals in Cohorts A–C with an MDD diagnosis were analyzed by year of MDD onset (Cohorts A–C(MDD2015–2019)). Diagnoses and median medical costs were derived from International Classification of Diseases 10 codes. RESULTS: Total medical and non-neuropsychiatric drug costs in MDD onset years were 170,390–182,120 and 8480–9586 yen higher, respectively, for Cohorts A(MDD2015–2019) than for Cohort A. In Cohort A(MDD2019), total medical and non-neuropsychiatric drug costs increased incrementally from 2015 to 2019 (total changes: + 165,130 and + 7365 yen, respectively), to a greater degree than in Cohort A (+ 10,510 and + 1246 yen, respectively). Neuropsychiatric drug costs increased in the year of MDD onset only and decreased thereafter. After MDD onset, decreases in total medical and non-neuropsychiatric drug costs were observed (Cohorts A(MDD2015–2019)). Non-neuropsychiatric drug costs also decreased after MDD onset in the chronic disease groups (Cohorts C(MDD)(2015–2019)), but not in patients with MDD recurrence. CONCLUSION: Treating MDD reduces medical costs for comorbid physical conditions and may be a useful strategy for improving healthcare efficiency in Japan. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01963-9.
format Online
Article
Text
id pubmed-8989836
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-89898362022-04-22 Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data Cho, Yoshinori Mishiro, Izumi Fujimoto, Shinji Nakajima, Tadashi Adv Ther Original Research INTRODUCTION: We aimed to clarify medical expenses in Japanese individuals before and after major depressive disorder (MDD) diagnosis, and to determine whether MDD treatment also reduces medical costs for comorbid physical conditions. METHODS: This was an exploratory, descriptive, retrospective analysis of insurance claims data from JMDC Inc. Cohort A included individuals aged 18–64 years between January 2015 and December 2019. Cohorts B and C included Cohort A individuals with diabetes/hypertension (‘chronic disease’), and sleep/anxiety disorders (‘high depression risk’), respectively. Individuals in Cohorts A–C with an MDD diagnosis were analyzed by year of MDD onset (Cohorts A–C(MDD2015–2019)). Diagnoses and median medical costs were derived from International Classification of Diseases 10 codes. RESULTS: Total medical and non-neuropsychiatric drug costs in MDD onset years were 170,390–182,120 and 8480–9586 yen higher, respectively, for Cohorts A(MDD2015–2019) than for Cohort A. In Cohort A(MDD2019), total medical and non-neuropsychiatric drug costs increased incrementally from 2015 to 2019 (total changes: + 165,130 and + 7365 yen, respectively), to a greater degree than in Cohort A (+ 10,510 and + 1246 yen, respectively). Neuropsychiatric drug costs increased in the year of MDD onset only and decreased thereafter. After MDD onset, decreases in total medical and non-neuropsychiatric drug costs were observed (Cohorts A(MDD2015–2019)). Non-neuropsychiatric drug costs also decreased after MDD onset in the chronic disease groups (Cohorts C(MDD)(2015–2019)), but not in patients with MDD recurrence. CONCLUSION: Treating MDD reduces medical costs for comorbid physical conditions and may be a useful strategy for improving healthcare efficiency in Japan. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01963-9. Springer Healthcare 2021-11-02 2022 /pmc/articles/PMC8989836/ /pubmed/34729704 http://dx.doi.org/10.1007/s12325-021-01963-9 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Cho, Yoshinori
Mishiro, Izumi
Fujimoto, Shinji
Nakajima, Tadashi
Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data
title Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data
title_full Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data
title_fullStr Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data
title_full_unstemmed Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data
title_short Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data
title_sort impact of depression onset and treatment on the trend of annual medical costs in japan: an exploratory, descriptive analysis of employer-based health insurance claims data
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989836/
https://www.ncbi.nlm.nih.gov/pubmed/34729704
http://dx.doi.org/10.1007/s12325-021-01963-9
work_keys_str_mv AT choyoshinori impactofdepressiononsetandtreatmentonthetrendofannualmedicalcostsinjapananexploratorydescriptiveanalysisofemployerbasedhealthinsuranceclaimsdata
AT mishiroizumi impactofdepressiononsetandtreatmentonthetrendofannualmedicalcostsinjapananexploratorydescriptiveanalysisofemployerbasedhealthinsuranceclaimsdata
AT fujimotoshinji impactofdepressiononsetandtreatmentonthetrendofannualmedicalcostsinjapananexploratorydescriptiveanalysisofemployerbasedhealthinsuranceclaimsdata
AT nakajimatadashi impactofdepressiononsetandtreatmentonthetrendofannualmedicalcostsinjapananexploratorydescriptiveanalysisofemployerbasedhealthinsuranceclaimsdata